Assessment of Utilization Patterns of New Molecular Entities Approved in 2022 using the Sentinel Distributed Database

As new molecular entities (NMEs) enter clinical use, understanding their real-world uptake is key for post-market safety—especially given differences from trial populations. This poster features a Sentinel System study of 37 NMEs approved in 2022, using data from five Sentinel Distributed Database partners. The analysis details initiator demographics, treatment duration, dispensing frequency, and gaps in use. Uptake varied widely, with tirzepatide and faricimab-svoa—both for diabetes-related conditions—emerging as the most used. This poster was presented at the 2025 ISPE Annual Meeting.